Protagenic Therapeutics, Inc.
PTIX
$0.49
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.24% | 3.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.95% | -7.82% | |||
| Operating Income | 16.95% | 7.82% | |||
| Income Before Tax | 354.26% | 82.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 354.26% | 82.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 354.26% | 82.81% | |||
| EBIT | 16.95% | 7.82% | |||
| EBITDA | 17.14% | 7.90% | |||
| EPS Basic | 343.00% | 65.59% | |||
| Normalized Basic EPS | 343.06% | 65.60% | |||
| EPS Diluted | 343.00% | 65.59% | |||
| Normalized Diluted EPS | 343.06% | 65.60% | |||
| Average Basic Shares Outstanding | 4.62% | -50.03% | |||
| Average Diluted Shares Outstanding | 4.62% | -50.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||